An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 29 Jan 2019
At a glance
- Drugs GRANITE 001 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Bladder cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gritstone Oncology
- 21 Jan 2019 Planned initiation date changed from 1 Dec 2018 to 1 Jan 2019.
- 04 Dec 2018 Planned initiation date changed from 1 Oct 2018 to 1 Dec 2018.
- 04 Dec 2018 Status changed from not yet recruiting to recruiting.